Brief · Use case · Market Access
Payer Coverage Outlook.
LiveOutlookProject whether major US payers cover a new specialty therapy without step therapy within a year, with the base rate and the signposts to watch.
Payer Coverage Outlook is a ready-made use case for Market Access. It ships under the Outlook template.
For market access and HEOR leads planning a launch. You get the projected event and resolution test, the reference class for comparable launches, a range, scenarios and early signposts. Claims are cited or marked as gaps.
Add it to your library to reuse from New → From template. Edit the saved copy in your library on the service form.
The decision
Will the major United States commercial payers cover a newly approved specialty therapy without step therapy within 12 months of launch, and how likely is it?
What the outlook examines
Payers decide coverage and utilization management product by product, and few publish their reasoning. The outlook says what is public and what is judgment.
| Part of the outlook | What it asks | Where it looks |
|---|---|---|
| What payers ask for | The evidence dossier payers use to decide coverage. The Academy of Managed Care Pharmacy’s Format for Formulary Submissions, version 4.1 of December 2019, describes dossiers for unapproved products, approved products and unapproved uses, and is a guidance and not a mandate.1 | The AMCP Format. |
| What the manufacturer may share and when | FDA’s June 2018 guidance on manufacturer communications with payors describes the sharing of certain non-promotional information before approval.1 | The AMCP Format’s account of its alignment with the FDA guidance. |
| What is not public | Individual payers’ coverage criteria and the reasons for step therapy are often not published in a form that can be counted. The outlook says which payers publish policies and which do not. | Payers’ own published coverage policies, searched on a stated date. |
What the outlook does
No public base rate. The outlook did not find a published base rate for the share of newly launched specialty therapies covered without step therapy within a year. The base rate section says so, builds a reference class from payers’ published policies for comparable products, and labels the likelihood analyst judgment.
A resolvable question. The question names the payers, the date of launch and what counts as step therapy, and resolves on the payers’ published coverage policies on a stated date.
Evidence payers use. The AMCP Format is the common frame for the evidence dossier. The outlook checks whether the manufacturer’s evidence fits the frame, since a gap in the dossier is a likely reason for a restriction.1
Scenarios. At Comprehensive length the outlook sets out the scenarios: broad coverage at launch, coverage with step therapy that eases within a year, and restricted coverage that persists, each with a likelihood.
Recommended length
Comprehensive
The future could go several ways. Comprehensive adds the table of scenarios with their likelihoods.
You can pick another length on the form. The other two stay available.
Assumptions the outlook checks
The outlook states the assumptions its likelihood rests on and names the weakest one. Examples for this question:
- The payers’ published policies are the ones that apply to the plans the outlook counts.
- Step therapy, as defined in the question, can be read from the policies.
- The therapy is launched with a label that supports the coverage the outlook assumes.
Standards, guidance and sources
Payer evidence
The decision practice behind the memo itself is on the template page.
What gets flagged
Any likelihood that rests on judgment because no base rate exists, any payer whose policy is not public, and any definition of step therapy the outlook had to choose.
What arrives
- The projection
- Starting point and base rate
- What is already in motion
- The most likely path
- Scenarios
- What would change it
- Signposts
- Confidence, and where it is weakest
What it will not do
It does not predict with certainty or recommend an action. The likelihood carries a range, confidence is stated separately, and a Decision Memo uses the outlook as an input.
It does not predict a particular payer’s decision, and it does not advise on contracting.
It does not predict with certainty. A likelihood is a statement about the evidence, with a range, and the outlook says how sure it is separately.
It does not make a base rate from nothing. Where no reference class exists, the base rate table says so and the likelihood is labeled analyst judgment.
It does not recommend an action. A Decision Memo takes the outlook as an input.
References
- [1] Academy of Managed Care Pharmacy. AMCP Format for Formulary Submissions, Version 4.1. December 2019. Scope and status as given in AMCP’s release and search excerpts; the Format was not read in full. The FDA guidance is cited as AMCP describes it. Check whether a later version exists.
Links checked 9 October 2026
These are the sources the template drew on. None of their authors or issuers has reviewed it.
About the Brief service
A Brief is a written answer from one specialist, at the depth you asked for. It arrives with its sources, and it closes by saying plainly what would change the conclusion. Nothing is hidden behind a summary, and anything the expert could not source is marked as a gap rather than filled in.
To edit a saved template, open New → Brief → From template, or the library rail on the service form.